Source link : https://newshealth.biz/health-news/cemiplimab-extends-disease-free-time-in-skin-cancer-post-op/
TOPLINE: Adjuvant cemiplimab therapy reduced the risk for disease recurrence or death by 68% compared with placebo in patients with high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy. The 24-month disease-free survival rate was 87.1% vs 64.1% with cemiplimab vs placebo. METHODOLOGY: The primary treatment, surgery with curative intent, achieves a cure in approximately […]
The post Cemiplimab Extends Disease-Free Time in Skin Cancer Post-Op first appeared on News Health.
—-
Author : News Health
Publish date : 2025-08-19 06:01:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8